Please login to the form below

Not currently logged in
Email:
Password:

Pfizer phase III Lyrica success

Pfizer has recorded positive results in a phase III trial of fibromyalgia treatment Lyrica

Pfizer has recorded positive results in a phase III trial of Lyrica (pregabalin), a potential new treatment for fibromyalgia -  a disabling disorder that adversely affects quality of life.

The study demonstrated a statistically significant reduction in the endpoint mean pain score recorded by participants, with the drug demonstrating efficacy and safety.

The drug was compared to placebo, with 501 subjects involved across 45 investigative sites in Japan.

"We are pleased with the top-line results of this study and look forward to more fully understanding the potential benefits that Lyrica may bring to fibromyalgia patients in Japan," said Dr Akihisa Harada, vice president, head of development, at Pfizer Japan.

The most common adverse events in the study were somnolence, dizziness, weight increased, constipation, feeling abnormal, edema peripheral and blurred vision.

7th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics